323 related articles for article (PubMed ID: 36991347)
1. Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study.
Jin P; Shen J; Yang L; Zhang J; Shen A; Bao J; Wang X
BMC Med Imaging; 2023 Mar; 23(1):47. PubMed ID: 36991347
[TBL] [Abstract][Full Text] [Related]
2. [The value of machine learning models based on biparametric MRI for diagnosis of prostate cancer and clinically significant prostate cancer].
Qiao XM; Hu CH; Hu S; Hu CH; Wang XM; Shen JK; Ji LB; Song Y; Bao J
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1446-1454. PubMed ID: 37198106
[No Abstract] [Full Text] [Related]
3. Magnetic Resonance Imaging Radiomics-Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions.
Hectors SJ; Chen C; Chen J; Wang J; Gordon S; Yu M; Al Hussein Al Awamlh B; Sabuncu MR; Margolis DJA; Hu JC
J Magn Reson Imaging; 2021 Nov; 54(5):1466-1473. PubMed ID: 33970516
[TBL] [Abstract][Full Text] [Related]
4. Bi-parametric magnetic resonance imaging based radiomics for the identification of benign and malignant prostate lesions: cross-vendor validation.
Ji X; Zhang J; Shi W; He D; Bao J; Wei X; Huang Y; Liu Y; Chen JC; Gao X; Tang Y; Xia W
Phys Eng Sci Med; 2021 Sep; 44(3):745-754. PubMed ID: 34075559
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions.
Li T; Sun L; Li Q; Luo X; Luo M; Xie H; Wang P
Front Oncol; 2021; 11():825429. PubMed ID: 35155214
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters.
Woźnicki P; Westhoff N; Huber T; Riffel P; Froelich MF; Gresser E; von Hardenberg J; Mühlberg A; Michel MS; Schoenberg SO; Nörenberg D
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630787
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
8. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
9. A radiomics machine learning-based redefining score robustly identifies clinically significant prostate cancer in equivocal PI-RADS score 3 lesions.
Hou Y; Bao ML; Wu CJ; Zhang J; Zhang YD; Shi HB
Abdom Radiol (NY); 2020 Dec; 45(12):4223-4234. PubMed ID: 32740863
[TBL] [Abstract][Full Text] [Related]
10. Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature.
Zhang L; Zhe X; Tang M; Zhang J; Ren J; Zhang X; Li L
Contrast Media Mol Imaging; 2021; 2021():7830909. PubMed ID: 35024015
[TBL] [Abstract][Full Text] [Related]
11. Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation.
Kan Y; Zhang Q; Hao J; Wang W; Zhuang J; Gao J; Huang H; Liang J; Marra G; Calleris G; Oderda M; Zhao X; Gontero P; Guo H
Eur Radiol; 2020 Nov; 30(11):6274-6284. PubMed ID: 32524222
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging radiomics-based prediction of clinically significant prostate cancer in equivocal PI-RADS 3 lesions in the transitional zone.
Zhao YY; Xiong ML; Liu YF; Duan LJ; Chen JL; Xing Z; Lin YS; Chen TH
Front Oncol; 2023; 13():1247682. PubMed ID: 38074651
[TBL] [Abstract][Full Text] [Related]
13. Texture analysis based on PI-RADS 4/5-scored magnetic resonance images combined with machine learning to distinguish benign lesions from prostate cancer.
Ma L; Zhou Q; Yin H; Ang X; Li Y; Xie G; Li G
Transl Cancer Res; 2022 May; 11(5):1146-1161. PubMed ID: 35706813
[TBL] [Abstract][Full Text] [Related]
14. Predicting clinically significant prostate cancer with a deep learning approach: a multicentre retrospective study.
Zhao L; Bao J; Qiao X; Jin P; Ji Y; Li Z; Zhang J; Su Y; Ji L; Shen J; Zhang Y; Niu L; Xie W; Hu C; Shen H; Wang X; Liu J; Tian J
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):727-741. PubMed ID: 36409317
[TBL] [Abstract][Full Text] [Related]
15. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
[TBL] [Abstract][Full Text] [Related]
16. Predicting prostate cancer in men with PSA levels of 4-10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance.
Zhong JG; Shi L; Liu J; Cao F; Ma YQ; Zhang Y
Sci Rep; 2023 Mar; 13(1):4846. PubMed ID: 36964192
[TBL] [Abstract][Full Text] [Related]
17. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
18. Radiomics from multisite MRI and clinical data to predict clinically significant prostate cancer.
Krauss W; Frey J; Heydorn Lagerlöf J; Lidén M; Thunberg P
Acta Radiol; 2024 Mar; 65(3):307-317. PubMed ID: 38115809
[TBL] [Abstract][Full Text] [Related]
19. Utility of machine learning of apparent diffusion coefficient (ADC) and T2-weighted (T2W) radiomic features in PI-RADS version 2.1 category 3 lesions to predict prostate cancer diagnosis.
Lim CS; Abreu-Gomez J; Thornhill R; James N; Al Kindi A; Lim AS; Schieda N
Abdom Radiol (NY); 2021 Dec; 46(12):5647-5658. PubMed ID: 34467426
[TBL] [Abstract][Full Text] [Related]
20. Avoiding Unnecessary Systematic Biopsy in Clinically Significant Prostate Cancer: Comparison Between MRI-Based Radiomics Model and PI-RADS Category.
Cheng X; Chen Y; Xu H; Ye L; Tong S; Li H; Zhang T; Tian S; Qi J; Zeng H; Yao J; Song B
J Magn Reson Imaging; 2023 Feb; 57(2):578-586. PubMed ID: 35852438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
